Reuters logo
2 months ago
BRIEF-FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for prophylaxis of attacks in patients with acute hepatic porphyria
May 31, 2017 / 2:38 PM / 2 months ago

BRIEF-FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for prophylaxis of attacks in patients with acute hepatic porphyria

1 Min Read

May 31 (Reuters) - Alnylam Pharmaceuticals Inc

* FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for the prophylaxis of attacks in patients with acute hepatic porphyria

* Company plans to initiate phase 3 clinical program in late 2017

* ‍Updated results from trial to be provided in oral presentation on June 26 at International Congress On Porphyrins and Porphyrias​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below